Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development of antibody-based medicines for the treatment of diseases caused by oxidative stress
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
PRESS RELEASE Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development…
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen…
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary…
Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging…
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing…
This announcement contains inside information for the purposes of Article 7 of the Market Abuse…
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma…
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…